secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silexion Therapeutics Corp (SLXN)
CIK:        0002022416
Form:       8-K
Filed at:   2025-03-28T23:59:59+00:00
Accession:  0001178913-25-001103
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silexion expands SIL204 development with dual-route plan; preclinical data support; H1 2026 human trials targeted
--------------------------------------------------------------------------------

- Expanded development plan for SIL204 combines intratumoral and systemic administration for KRAS-driven pancreatic cancer.
- Preclinical orthotopic model data show systemic SIL204 significantly inhibits tumor growth and reduces metastases.
- Toxicology and pharmacodynamic studies planned through 2025; regulatory submissions to Israel Ministry of Health in H2 2025 and EU in H1 2026.
- Goal to initiate SIL204 human trials in H1 2026 for advanced localized KRAS-driven pancreatic cancer.
- First-generation product siG12DLoder previously showed overall survival benefit in Phase 2, supporting the expanded approach.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2022416/000117891325001103/0001178913-25-001103-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2022416/000117891325001103/zk2532912.htm
  HTML page:      https://secwatch.observer/filing/0001178913-25-001103

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer